Why Ligand Pharmaceuticals Incorporated (LGND) stock moved
Ligand Pharmaceuticals Incorporated (LGND) shares fell 2.7% to $295.25 as of July 20, 2026, a moderate decline from the prior close of $303.39. BestStocks flagged the session as a major change for LGND. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for LGND, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
LGND fell 2.7% to $295.25
LGND fell 2.7% in its latest session, moving from $303.39 to $295.25.
What it means for Ligand Pharmaceuticals Incorporated investors
For Ligand Pharmaceuticals Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Ligand Pharmaceuticals Incorporated (LGND) moved +2.45% from $314.88 to $322.61 on 2026-07-09, reaching a new 30-day high; LGND moved +0.27% from $319.55 to $320.42 on 2026-07-06. Weighing against that: Negative session, down 2.7%; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $326.50, implying +10.6% upside from $295.25. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 17 days out, the next report is the most likely near-term test of the move.
LGND price reaction
LGND last traded at $295.25, down $8.14 (-2.68%) from the previous close of $303.39. The session traded on 1.0× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $262.17 and $322.61, and it currently sits about 55% of the way up that band.
Bullish and bearish analyst opinions on Ligand Pharmaceuticals Incorporated (LGND)
The consensus analyst price target on Ligand Pharmaceuticals Incorporated (LGND) is $326.50, 10.6% above the recent $295.25. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LGND line up.
The bullish case
- Wall Street's consensus price target of $326.50 implies +10.6% upside from $295.25.
- The Street's most bullish target is $345.00 (+16.9%).
- Ligand Pharmaceuticals Incorporated (LGND) moved +2.45% from $314.88 to $322.61 on 2026-07-09, reaching a new 30-day high.
- LGND moved +0.27% from $319.55 to $320.42 on 2026-07-06.
The bearish case
- The most bearish analyst target is $289.00 (-2.1%).
- Negative session, down 2.7%.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for LGND
Frequently asked questions about LGND
Why did Ligand Pharmaceuticals Incorporated (LGND) stock move?
LGND fell 2.7% to $295.25. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did LGND stock fall?
LGND lost 2.68% ($8.14) versus the prior close of $303.39, last trading at $295.25 on 1.0× average volume.
When is Ligand Pharmaceuticals Incorporated's next earnings date?
LGND's next earnings report is estimated for 2026-08-06 — about 17 days away.
What is the analyst price target for LGND?
The consensus analyst price target for LGND is $326.50, about 10.6% above the current $295.25. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks LGND
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared LGND-specific materiality thresholds, triggering an evidence check. It draws on 7 tracked change events for LGND, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.